UPDATE: Baird Assumes argenx SE (ARGX) at Outperform

Baird analyst Joel Beatty assumes coverage on argenx SE (NASDAQ: ARGX) with a Outperform rating and a price target of $346.00.

The analyst comments "We rate ARGX Outperform largely because we see strong sales potential for lead agent
efgartigimod across multiple autoimmune diseases, with a differentiated mechanism compared to competitors. We see potential for the R&D Day event in July to incrementally increase the amount of credit investors attribute to additional indications for efgartigimod, as well as to pipeline agents beyond efgartigimod."

For an analyst ratings summary and ratings history on argenx SE click here. For more ratings news on argenx SE click here.

Shares of argenx SE closed at $268.12 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)